FORTIFERRUM P POWDER (Each sachet contains Promitor 70-soluble fiber/Iron pyrophosphate sunactive FE-P80LK micronized microencapsulated/L-ascorbic acid/Vitamin D3/cyanocobalamin/Folate-Vitamin B9 500mg/30mg of Iron/60mg/2/2.5mg/0.4mg)

Mechanism of action

Cyanocobalamin serves as a cofactor for methionine synthase and L-methylmalonyl-CoA mutase enzymes. Methionine synthase is essential for the synthesis of purines and pyrimidines that form DNA. L-methylmalonyl-CoA mutase is involved in the degradation of propionate, crucial for fat and protein metabolism. The lack of vitamin B12 results in the accumulation of methylmalonyl CoA, contributing to neurological manifestations. Additionally, it is vital for the synthesis of methionine from homocysteine, and its deficiency can lead to functional folate deficiency, which impacts red blood cell formation.

Pharmacodynamics

Cyanocobalamin corrects vitamin B12 deficiency and alleviates symptoms and laboratory abnormalities associated with pernicious anemia, such as megaloblastic indices, gastrointestinal lesions, and neurological damage. It is essential for growth, cell reproduction, hematopoiesis, nucleoprotein, and myelin synthesis. The drug significantly impacts fat and carbohydrate metabolism, as well as protein synthesis. Rapidly dividing cells, such as those in the bone marrow, have a high demand for vitamin B12. Parenteral administration of cyanocobalamin can quickly reverse the anemia and gastrointestinal symptoms of vitamin B12 deficiency, while also preventing the progression of related neurological damage.

Pharmacokinetics

Cyanocobalamin is absorbed in the intestine, primarily in the ileum, via specific transport mechanisms that may be impaired in individuals with intrinsic factor deficiency (as seen in pernicious anemia). Once absorbed, it is widely distributed in body tissues, with significant concentrations found in the liver, kidneys, and heart. The vitamin is stored in the liver, where it can be released into circulation as needed. Cyanocobalamin undergoes conversion to its active forms, methylcobalamin and adenosylcobalamin, which are utilized in various metabolic processes. The elimination half-life is variable, but it is generally excreted via urine as metabolites

Adverse effects

• Abdominal distension
• Decreased appetite
• Flatulence
• Nausea

Interactions

• Folic acid may interact with cyanocobalamin, especially in cases of megaloblastic anemia caused by folate deficiency.

Precautions

• Should not be given alone for pernicious anemia.
• Use caution in patients with Leber's disease, as it may worsen optic atrophy.

Pregnancy

Cyanocobalamin is essential during pregnancy as it helps prevent neural tube defects. It is advised that females of childbearing potential take 5 mg of folic acid daily before conception and throughout pregnancy.

Breast-feeding

Cyanocobalamin is generally considered safe during breastfeeding, but it is advised to monitor the infant for any adverse effects.

Storage

Store in a cool, dry place, away from direct sunlight. Protect from moisture.

Formulations

• Tablet: 1000 micrograms
• Tablet: 500 micrograms
• Tablet: 100 micrograms
• Oral solution: 50 micrograms per ml
• Solution for injection: 1000 micrograms per ml

Indications

• Vitamin D deficiency
• Rickets
• Osteomalacia
• Osteoporosis
• Hypoparathyroidism

Dosage

Adults: The usual adult dose for vitamin D deficiency is 800 to 2000 IU daily, depending on the severity of deficiency and clinical condition. Higher doses may be used under medical supervision.

Mechanism of action

Cholecalciferol is converted to its active forms, 25-hydroxyvitamin D in the liver and 1,25-dihydroxyvitamin D in the kidneys. These metabolites enhance the intestinal absorption of calcium and phosphorus, increase serum calcium levels, and mobilize these minerals from bone. This process is regulated by parathyroid hormone, which influences calcium and phosphate metabolism, particularly in the kidneys.

Pharmacodynamics

The pharmacodynamics of cholecalciferol involve its conversion to active metabolites that play a significant role in calcium and phosphorus homeostasis. The metabolites facilitate intestinal absorption of these minerals, promote bone mineralization, and influence renal reabsorption. The onset of action occurs within 10 to 24 hours following administration, as metabolic activation is required for its biological effects.

Pharmacokinetics

Cholecalciferol is absorbed in the gastrointestinal tract, and its absorption is enhanced by the presence of dietary fats. It is transported in the bloodstream bound to vitamin D-binding protein. Once in the liver, it undergoes hydroxylation to form 25-hydroxyvitamin D, which is further converted in the kidneys to the active form, 1,25-dihydroxyvitamin D. The elimination half-life of cholecalciferol varies, typically spanning several days, and it is primarily excreted in bile and urine.

Adverse effects

• Hypercalcemia
• Hypercalciuria
• Nausea
• Vomiting
• Constipation
• Weakness
• Fatigue

Interactions

• May enhance the effects of thiazide diuretics, leading to increased risk of hypercalcemia
• Anticonvulsants may increase metabolism of vitamin D, leading to reduced effectiveness
• Cholestyramine may reduce absorption of vitamin D

Precautions

• Monitor serum calcium levels in patients with renal impairment
• Caution in patients with a history of hypercalcemia or hyperparathyroidism
• Use with caution in patients taking other medications that affect calcium metabolism

Pregnancy

Cholecalciferol can be used during pregnancy if indicated, as vitamin D is essential for fetal bone development.

Breast-feeding

Cholecalciferol is excreted in breast milk, but is generally considered safe during breastfeeding.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Formulations

• Capsules
• Tablets
• Liquid formulations

Indications

• Constipation
• Irritable bowel syndrome (IBS)
• Diverticulitis
• Hyperlipidemia
• Type 2 diabetes management
• Weight management

Dosage

Children: For children, the recommended daily intake of fiber varies by age and is approximately 14 grams per 1,000 calories consumed. It is advisable to refer to specific pediatric guidelines for more detailed dosing.

Adults: The general recommendation for adults is to consume 25 to 30 grams of dietary fiber daily from food sources, rather than supplements, to promote optimal health.

Mechanism of action

Fiber works primarily by adding bulk to the stool and facilitating regular bowel movements. Soluble fiber dissolves in water to form a gel-like substance, which can help to slow digestion and regulate blood sugar levels by slowing the absorption of sugar. Insoluble fiber does not dissolve in water and helps food pass more quickly through the stomach and intestines.

Pharmacodynamics

The pharmacodynamics of fiber involve its ability to enhance gastrointestinal health. Soluble fiber can lower cholesterol levels, improve glycemic control, and promote satiety, which may assist in weight management. Insoluble fiber contributes to increased stool bulk and can help prevent constipation. The fermentation of soluble fiber in the colon produces short-chain fatty acids, which have various health benefits, including anti-inflammatory effects.

Pharmacokinetics

Fiber is not absorbed in the gastrointestinal tract; thus, it has no bioavailability. It passes through the stomach and small intestine largely intact, reaching the colon where it can be fermented by gut microbiota. The rate of fermentation and the production of short-chain fatty acids can vary based on the type of fiber consumed and the individual's gut microbiome.

Adverse effects

• Bloating
• Gas
• Abdominal cramps
• Diarrhea
• Constipation

Precautions

• Increase fiber intake gradually to avoid gastrointestinal discomfort.
• Adequate fluid intake is necessary to prevent constipation.
• Caution is advised in patients with gastrointestinal disorders.

Pregnancy

Fiber is generally considered safe during pregnancy. It supports digestive health and can help alleviate constipation common in this population.

Breast-feeding

Fiber is safe during breastfeeding and can aid in postpartum digestive health.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• Powder
• Capsules
• Tablets
• Granules
• Natural food sources (fruits, vegetables, whole grains)

Indications

• Chronic pain management
• Hormonal therapies
• Antibiotic formulations
• Vaccines
• Nutritional supplements

Dosage

Children: Refer to specific drug formulations and BNF for Children for appropriate dosing guidelines, as microencapsulation is a method used for various drugs and does not have a standard dosage.

Adults: Refer to specific drug formulations and BNF for appropriate dosing guidelines, as microencapsulation is a method used for various drugs and does not have a standard dosage.

Mechanism of action

Microencapsulation itself does not have a specific mechanism of action as it is a formulation technique. However, the encapsulation can modify the pharmacokinetics and pharmacodynamics of the drug it contains. By controlling the rate of release, microencapsulation can maintain therapeutic drug levels over an extended period, reduce side effects, and improve the overall efficacy of the drug.

Pharmacodynamics

The pharmacodynamic properties of microencapsulated drugs depend on the active substance encapsulated. Generally, microencapsulation allows for a sustained or controlled release of the drug, which can lead to improved therapeutic outcomes and reduced frequency of dosing. This can minimize peak-trough fluctuations and enhance the safety profile of the medication.

Pharmacokinetics

Microencapsulation can alter the pharmacokinetic profile of the drug, affecting absorption, distribution, metabolism, and excretion (ADME). The rate of drug release from the microcapsules can determine the absorption rate in the gastrointestinal tract, potentially leading to increased bioavailability. Additionally, the polymer or material used for encapsulation may influence the drug's solubility and stability, impacting how it is metabolized and eliminated from the body.

Pregnancy

The safety of microencapsulated formulations during pregnancy has not been extensively studied. Use only if clearly needed and after evaluating the potential risks and benefits.

Breast-feeding

It is unclear whether microencapsulated substances are excreted in human milk. Caution is advised when administering to breastfeeding women.

Storage

Store at room temperature, away from moisture and direct sunlight. Check specific product labels for any additional storage instructions.

Indications

• Enhanced absorption of poorly soluble drugs
• Improved therapeutic effectiveness of various medications

Dosage

Children: Refer to specific drug formulations for dosing information, as dosages can vary widely based on the active ingredient.

Adults: Refer to specific drug formulations for dosing information, as dosages can vary widely based on the active ingredient.

Mechanism of action

Micronization itself does not alter the pharmacological activity of the drug; rather, it enhances the drug's absorption characteristics. This is particularly significant for drugs that are poorly soluble, as increased absorption can lead to more effective therapeutic outcomes.

Pharmacodynamics

The pharmacodynamics of micronized drugs remain consistent with the pharmacological profile of the active ingredient. Micronized drugs often exhibit enhanced onset of action due to increased absorption rates, leading to quicker therapeutic effects. However, the specific effects will depend on the drug and its mechanism of action.

Pharmacokinetics

Micronization can significantly influence the pharmacokinetics of a drug by improving its absorption in the gastrointestinal tract. This may lead to increased peak plasma concentrations and altered time to peak effect. The elimination half-life and volume of distribution may remain unchanged, but the overall bioavailability may be improved.

Pregnancy

Micronized formulations should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consultation with a healthcare provider is recommended.

Breast-feeding

Caution is advised when using micronized drugs while breastfeeding. The effects on the infant should be considered, and consultation with a healthcare provider is recommended.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Chronic constipation
• Constipation-predominant irritable bowel syndrome

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations.

Adults: Refer to the BNF for specific dosing recommendations.

Mechanism of action

Promitor works by selectively binding to and activating the serotonin 5-HT4 receptors in the gastrointestinal tract. This action leads to an increase in the release of acetylcholine, which stimulates colonic motility and enhances bowel transit time. The drug's efficacy is attributed to its ability to enhance the peristaltic reflex and increase the frequency of bowel movements.

Pharmacodynamics

By activating the 5-HT4 receptors, promitor promotes the release of neurotransmitters involved in gut motility. This results in increased contraction of the smooth muscle in the intestinal walls, leading to more coordinated and effective bowel movements. The drug has been shown to significantly improve symptoms of constipation in clinical trials, including abdominal discomfort and straining during defecation.

Pharmacokinetics

Promitor is well absorbed after oral administration, with peak plasma concentrations occurring within 1 to 2 hours. The drug undergoes extensive hepatic metabolism, primarily via the cytochrome P450 system, and is eliminated mainly through the urine. The half-life of promitor is approximately 24 hours, allowing for once-daily dosing.

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Dizziness
• Headache
• Fatigue
• Insomnia

Interactions

• CYP3A4 inhibitors may increase promitor levels
• CYP3A4 inducers may decrease promitor effectiveness
• Concurrent use with other CNS depressants may increase sedation

Precautions

• Use with caution in patients with a history of seizures
• Monitor renal and hepatic function during therapy
• Assess for potential drug abuse in patients with a history of substance use disorder

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether promitor is excreted in human milk. Exercise caution when administering to nursing mothers.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Tablets
• Oral solution

Dosage

Children: Refer to specific clinical guidelines or pharmacological references for dosing information.

Adults: Refer to specific clinical guidelines or pharmacological references for dosing information.

Mechanism of action

Pyrophosphate functions primarily as an energy donor in biochemical reactions, particularly in the hydrolysis of ATP to ADP and inorganic phosphate, releasing energy. It is involved in the activation of substrates for biosynthetic reactions and serves as a source of phosphate for phosphorylation processes. Its role in fatty acid oxidation, amino acid metabolism, and tRNA charging underscores its importance in cellular metabolism.

Pharmacodynamics

Pyrophosphate has a significant impact on metabolic pathways by influencing the energy transfer processes within the cell. It is involved in the regulation of enzymatic activities, particularly those that require the transfer of phosphate groups. The presence of pyrophosphate can affect the equilibrium of reversible reactions, thereby influencing cellular metabolism and energy homeostasis.

Pharmacokinetics

The pharmacokinetics of pyrophosphate are not typically characterized in the same manner as conventional drugs, as it is a naturally occurring compound in the body. Its absorption, distribution, metabolism, and excretion are largely dependent on its role in cellular metabolism and its involvement in various biochemical pathways. Pyrophosphate is metabolized rapidly in vivo, and its levels are tightly regulated by cellular processes.

Indications

• Magnesium deficiency
• Muscle cramps
• Fatigue
• Support for energy metabolism
• Enhancement of muscle function

Dosage

Children: Refer to established guidelines for paediatric dosing, as it may vary based on age, weight, and clinical condition.

Adults: Dosage should be determined based on individual needs and clinical recommendations; refer to appropriate guidelines for specific dosing.

Mechanism of action

Magnesium aspartate is known to facilitate various enzymatic reactions, particularly those involved in energy metabolism. It acts as a cofactor for ATP (adenosine triphosphate) synthesis, which is vital for energy production in cells. Additionally, magnesium plays a crucial role in neuromuscular transmission and muscle contraction, influencing both relaxation and contraction of muscles.

Pharmacodynamics

Magnesium aspartate exerts its effects by replenishing magnesium levels in the body, which can help mitigate symptoms associated with magnesium deficiency, such as muscle cramps, fatigue, and weakness. Adequate magnesium levels are essential for maintaining normal nerve function, muscle contraction, and bone health. It may also have a role in modulating inflammatory responses and supporting cardiovascular health.

Pharmacokinetics

Once ingested, magnesium aspartate is absorbed in the gastrointestinal tract, with its bioavailability influenced by factors such as gastrointestinal pH and the presence of other dietary components. It is distributed throughout the body, primarily in bones, muscles, and soft tissues. Magnesium is excreted mainly through the kidneys, with renal function significantly affecting magnesium levels in the body. The half-life of magnesium in the body varies, but it is generally several hours, with effects lasting longer depending on cellular uptake and storage.

Pregnancy

Consult healthcare provider before use, as safety during pregnancy has not been established.

Breast-feeding

Consult healthcare provider before use, as safety during breastfeeding has not been established.

Storage

Store in a cool, dry place away from direct sunlight.

Mechanism of action

Vitamin B12 serves as a cofactor for _methionine synthase_ and _L-methylmalonyl-CoA mutase_ enzymes. Methionine synthase is essential for the synthesis of purines and pyrimidines that form DNA. L-methylmalonyl-CoA mutase converts L-methylmalonyl-CoA to _succinyl-CoA_ in the degradation of propionate, an important reaction required for both fat and protein metabolism. It is a lack of vitamin B12 cofactor in the above reaction and the resulting accumulation of methylmalonyl CoA that is believed to be responsible for the neurological manifestations of B12 deficiency. Succinyl-CoA is also necessary for the synthesis of hemoglobin. In tissues, vitamin B12 is required for the synthesis of _methionine_ from homocysteine. Methionine is required for the formation of S-adenosylmethionine, a methyl donor for nearly 100 substrates, comprised of DNA, RNA, hormones, proteins, as well as lipids. Without vitamin B12, tetrahydrofolate cannot be regenerated from 5-methyltetrahydrofolate, and this can lead to functional folate deficiency,. This reaction is dependent on methylcobalamin (vitamin B12) as a co-factor and is also dependent on folate, in which the methyl group of methyltetrahydrofolate is transferred to homocysteine to form _methionine_ and _tetrahydrofolate_. Vitamin B12 incorporates into circulating folic acid into growing red blood cells; retaining the folate in these cells. A deficiency of vitamin B12 and the interruption of this reaction leads to the development of megaloblastic anemia.

Pharmacodynamics

**General effects** Cyanocobalamin corrects vitamin B12 deficiency and improves the symptoms and laboratory abnormalities associated with pernicious anemia (megaloblastic indices, gastrointestinal lesions, and neurologic damage). This drug aids in growth, cell reproduction, hematopoiesis, nucleoprotein, and myelin synthesis. It also plays an important role in fat metabolism, carbohydrate metabolism, as well as protein synthesis. Cells that undergo rapid division (for example, epithelial cells, bone marrow, and myeloid cells) have a high demand for vitamin B12. **Parenteral cyanocobalamin effects** The parenteral administration of vitamin B12 rapidly and completely reverses the megaloblastic anemia and gastrointestinal symptoms of vitamin B12 deficiency. Rapid parenteral administration of vitamin B12 in deficiency related neurological damage prevents the progression of this condition. **Nasal spray effects** In 24 vitamin B12 deficient patients who were already stabilized on intramuscular (IM) vitamin B12 therapy, single daily doses of intranasal cyanocobalamin for 8 weeks lead to serum vitamin B12 concentrations that were within the target therapeutic range (>200 ng/L).

Mechanism of action

Most individuals naturally generate adequate amounts of vitamin D through ordinary dietary intake of vitamin D (in some foods like eggs, fish, and cheese) and natural photochemical conversion of the vitamin D3 precursor 7-dehydrocholesterol in the skin via exposure to sunlight. Conversely, vitamin D deficiency can often occur from a combination of insufficient exposure to sunlight, inadequate dietary intake of vitamin D, genetic defects with endogenous vitamin D receptor, or even severe liver or kidney disease. Such deficiency is known for resulting in conditions like rickets or osteomalacia, all of which reflect inadequate mineralization of bone, enhanced compensatory skeletal demineralization, resultant decreased calcium ion blood concentrations, and increases in the production and secretion of parathyroid hormone. Increases in parathyroid hormone stimulate the mobilization of skeletal calcium and the renal excretion of phosphorus. This enhanced mobilization of skeletal calcium leads towards porotic bone conditions. Ordinarily, while vitamin D3 is made naturally via photochemical processes in the skin, both itself and vitamin D2 can be found in various food and pharmaceutical sources as dietary supplements. The principal biological function of vitamin D is the maintenance of normal levels of serum calcium and phosphorus in the bloodstream by enhancing the efficacy of the small intestine to absorb these minerals from the diet. At the liver, vitamin D3 or D2 is hydroxylated to 25-hydroxyvitamin D and then finally to the primary active metabolite 1,25-dihydroxyvitamin D in the kidney via further hydroxylation. This final metabolite binds to endogenous vitamin d receptors, which results in a variety of regulatory roles - including maintaining calcium balance, the regulation of parathyroid hormone, the promotion of the renal reabsorption of calcium, increased intestinal absorption of calcium and phosphorus, and increased calcium and phosphorus mobilization of calcium and phosphorus from bone to plasma to maintain balanced levels of each in bone and the plasma. In particular, calcitriol interacts with vitamin D receptors in the small intestine to enhance the efficiency of intestinal calcium and phosphorous absorption from about 10-15% to 30-40% and 60% increased to 80%, respectively. Furthermore, calcitriol binds with vitamin D receptors in osteoblasts to stimulate a receptor activator of nuclear factor kB ligand (or RANKL) which subsequently interacts with receptor activator of nuclear factor kB (NFkB) on immature preosteoclasts, causing them to become mature bone-resorbing osteoclasts. Such mature osteoclasts ultimately function in removing calcium and phosphorus from bone to maintain blood calcium and phosphorus levels. Moreover, calcitriol also stimulates calcium reabsorption from the glomerular filtrate in the kidneys. Additionally, it is believed that when calcitriol binds with nuclear vitamin D receptors, that this bound complex itself binds to retinoic acid X receptor (RXR) to generate a heterodimeric complex that consequently binds to specific nucleotide sequences in the DNA called vitamin D response elements. When bound, various transcription factors attach to this complex, resulting in either up or down-regulation of the associated gene's activity. It is thought that there may be as much as 200 to 2000 genes that possess vitamin D response elements or that are influenced indirectly to control a multitude of genes across the genome. It is in this way that cholecalciferol is believed to function in regulating gene transcription associated with cancer risk, autoimmune disorders, and cardiovascular disease linked to vitamin D deficiency. In fact, there has been some research to suggest calcitriol may also be able to prevent malignancies by inducing cellular maturation and inducing apoptosis and inhibiting angiogenesis, exhibit anti-inflammatory effects by inhibiting foam cell formation and promoting angiogenesis in en

Pharmacodynamics

The in vivo synthesis of the predominant two biologically active metabolites of vitamin D occurs in two steps. The first hydroxylation of vitamin D3 cholecalciferol (or D2) occurs in the liver to yield 25-hydroxyvitamin D while the second hydroxylation happens in the kidneys to give 1, 25-dihydroxyvitamin D. These vitamin D metabolites subsequently facilitate the active absorption of calcium and phosphorus in the small intestine, serving to increase serum calcium and phosphate levels sufficiently to allow bone mineralization. Conversely, these vitamin D metabolites also assist in mobilizing calcium and phosphate from bone and likely increase the reabsorption of calcium and perhaps also of phosphate via the renal tubules. There exists a period of 10 to 24 hours between the administration of cholecalciferol and the initiation of its action in the body due to the necessity of synthesis of the active vitamin D metabolites in the liver and kidneys. It is parathyroid hormone that is responsible for the regulation of such metabolism at the level of the kidneys.